Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of Intratumoral Alpha DaRT224 for the Treatment of Immunocompromised Patients With Cutaneous Squamous Cell Carcinoma

NCT06615635 is registered in ClinicalTrials.gov with Alpha Tau Medical LTD. as lead sponsor.

NCT NCT06615635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06615635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of Intratumoral Alpha DaRT224 for the Treatment of Immunocompromised Patients With Cutaneous Squamous Cell Carcinoma
Lead sponsor
Alpha Tau Medical LTD.
Phase
Not applicable
Overall status
Recruiting
Start date
January 1, 2026
Completion date
December 31, 2026
Enrollment
28 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alpha radiation, brachytherapy, carcinoma, squamous, immunocompromised, skin cancer, squamous cell carcinoma